A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

9 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-23

Study Completion Date

2018-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT03500549

Paroxysmal Nocturnal Hemoglobinuria

COMPLETED PHASE3

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

NCT04085601

Paroxysmal Nocturnal Hemoglobinuria

COMPLETED PHASE3

BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor Therapy

NCT05116787

Paroxysmal Nocturnal Hemoglobinuria (PNH)

TERMINATED PHASE2

A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT04702568

Paroxysmal Nocturnal Hemoglobinuria PNH

TERMINATED PHASE2

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

NCT00098280

Hemoglobinuria, Paroxysmal

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort 1

First Dose 25mg, Repeated Dose 5 mg/day

Group Type EXPERIMENTAL

Pegcetacoplan

Intervention Type DRUG

Complement (C3) Inhibitor

Cohort 2

First Dose 50 mg, Repeated Dose 30 mg/day

Group Type EXPERIMENTAL

Pegcetacoplan

Intervention Type DRUG

Complement (C3) Inhibitor

Cohort 3

Repeated Dose 180 mg/day

Group Type EXPERIMENTAL

Pegcetacoplan

Intervention Type DRUG

Complement (C3) Inhibitor

Cohort 4

Repeated Dose 270 mg/day

Group Type EXPERIMENTAL

Pegcetacoplan

Intervention Type DRUG

Complement (C3) Inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pegcetacoplan

Complement (C3) Inhibitor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

APL-2

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or Female
* At least 18 years of age
* Weigh \>55 kg
* Diagnosed with PNH
* On treatment with eculizumab (Soliris®) for at least 3 months
* Hb \< 10 g/dL at screening OR have received at least one transfusion within 12 months prior to screening
* Platelet count of \>30,000/mm3
* Absolute neutrophil count \> 500/mm3
* Women of child-bearing potential (WOCBP) must have a negative pregnancy test at screening and must agree to use protocol defined methods of contraception for the duration of the study (see below)
* Males with female partners of child bearing potential must agree to use protocol defined methods of contraception (see below) and agree to refrain from donating sperm for the duration of the study
* Willing and able to give informed consent

Exclusion Criteria

* Active bacterial infection
* Known infection with hepatitis B, C or HIV
* Hereditary complement deficiency
* History of bone marrow transplantation
* Participation in any other investigational drug trial or exposure to other investigational agent, device or procedure within 30 days
* Evidence of QTcF prolongation defined as \> 450 ms for males and \> 470 ms for females at screening
* Creatinine clearance (CrCl) \< 50 mL/min (Cockcroft-Gault formula) at screening
* Breast-feeding women
* History of meningococcal disease
* No vaccination against N. meningitidis types A, C, W, Y and B (administered as two separate vaccinations), Pneumococcal conjugate vaccine or Pneumococcal polysaccharide vaccine 23 (PCV13 or PPSV23, respectively) and Haemophilus influenzae Type B (Hib) vaccination within 2 years prior to Day 1 (Visit 2) dosing.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No